



Affymetrix Inc.**Media Contact:**

Justin O'Kelly
PR Manager
408-731-5991

Investor Contact:

Doug Farrell
Vice President, Investor Relations
408-731-5285

South African Core Lab Adopts Affymetrix Technology For Genomic Studies

Centre for Proteomic and Genomic Research aims to become the country's hub for microarray-based research

SANTA CLARA, Calif., October 7 2008 – Affymetrix Inc., (Nasdaq: AFFX) today announced that one of South Africa's largest public core labs has begun offering genomic research on the Affymetrix GeneChip® platform. The Centre for Proteomic and Genomic Research (CPGR) is using many Affymetrix GeneChip arrays, such as the exon array and the SNP Array 6.0, to explore applications with molecular diagnostics potential, large-scale genotyping and novel ways of advancing drug research and development across the country.

The CPGR supports scientists particularly in biomedicine and plant biotechnology. It has a particular interest in translational research, advancing scientific findings from the bench into the clinic. The Centre was founded in 2006 to provide state-of-the-art analytical services, technical expertise, project support and collaborative research capabilities in genomics and proteomics.

“At the CPGR, our aim is to facilitate high-quality research and enable the growth of existing southern African biotech companies,” said Reinhard Hiller, Ph.D., managing director of the CPGR. “The range of projects we work on is particularly diverse, so we appreciate the ability of Affymetrix to offer products that meet all our customers' needs, from toxicology to gene expression and genotyping.”

“The CPGR has assembled a team of world-class scientists to nourish the development of new biotech leaders by translating academic research into novel intellectual property and commercial ventures,” said Kevin King, president of Affymetrix. “With its adoption of the entire portfolio of array products available on our integrated microarray platform, the

Centre is setting new standards for microarray-based research which we believe will lead to important solutions for some of the region's most pressing diseases.”

About Affymetrix

Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,700 systems have been shipped around the world and more than 13,000 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., Cleveland, Ohio, and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company's website at www.affymetrix.com.

About CPGR

The Centre for Proteomic & Genomic Research (CPGR) is an integrated core technology facility, founded in South Africa in 2006 as a not-for-profit organization through a grant provided by the Department of Science and Technology (DST) by way of its vehicles the Cape Biotech Trust (CBT) and PlantBio (PB). Visit www.cpgr.org.za for more information or contact info@cpgr.org.za with specific requests.

Forward-looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties relating to commercial success of the agreement with the Centre for Proteomic and Genomic Research discussed in this press release; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties related to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties related to sole-source suppliers; risks associated with past and future acquisitions; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2007, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to

reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.